

# Chapter 195

## Poxvirus Infections

Caroline Piggott, Sheila Fallon Friedlander,  
& Wynn Tom

### REFERENCES

1. Diven DG: An overview of poxviruses. *J Am Acad Dermatol* **44**(1):1-16, 2001
2. Fenner F et al: *Smallpox and Its Eradication*. Geneva, Switzerland, World Health Organization, 1988
3. Huq F: Effect of temperature and relative humidity on variola virus in crusts. *Bull World Health Organ* **54**:710-712, 1976
4. Breman JG, Henderson DA: Diagnosis and management of smallpox. *N Engl J Med* **346**(17):1300-1308, 2002
5. Kiang KM, Krathwohl MD: Rates and risks of transmission of smallpox and mechanisms of prevention. *J Lab Clin Med* **142**(4):229-238, 2003
6. Henderson DA et al: Smallpox as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. *JAMA* **281**(22):2127-2137, 1999
7. Cohen J: Bioterrorism. Smallpox vaccinations: How much protection remains? *Science* **294**:985, 2001
8. Slifka MK, Hanifin JM: Smallpox: The basics. *Dermatol Clin* **22**(3):263-274, 2004
9. McFadden G: Killing a killer: What next for smallpox? *Pub Lib Sci Pathog* **29**(6):e1000727, 2010
10. Lupatkin H, Lupatkin JF, Rosenberg AD: Smallpox in the 21st century. *Anesthesiol Clin North America* **22**(3):541-561, 2004
11. Moore ZS, Seward JF, Lane JM: Smallpox. *Lancet* **367**:425-435, 2006
12. Fulginiti VA et al: Smallpox vaccination: A review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. *Clin Infect Dis* **37**(2):241-250, 2003
13. Guharoy R et al: Smallpox: Clinical features, prevention, and management. *Ann Pharmacother* **38**(3):440-447, 2004
14. Rao AR: *Smallpox*. Bombay, India, Kothari Book Depot, 1972
15. Nafziger SD: Smallpox. *Crit Care Clin* **21**(4):739-746, 2005
16. McKenzie PJ et al: Haemorrhagic smallpox. *Bull World Health Organ* **33**:773-782, 1965
17. Arora A, Agarwal A, Kumar S: Osteomyelitis variolosa: A report of two cases. *J Orthop Surg (Hong Kong)* **16**(3):355-358, 2008
18. Fenner F, Wittek R, Dumbell KR: *The Orthopoxviruses*. San Diego, Academic Press, 1989
19. Ropp SL et al: PCR strategy for identification and differentiation of small pox and other orthopoxviruses. *J Clin Microbiol* **33**(8):2069-2076, 1995
20. Kern ER: In vitro activity of potential anti-poxvirus agents. *Antiviral Res* **57**:35-40, 2003
21. Parker S et al: Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. *Antiviral Res* **77**(1):39-49, 2008
22. Jordan R et al: ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. *Antimicrob Agents Chemother* **53**(5):1817-1822 2009 Epub 2009 Feb 17.
23. Dixon CW: *Smallpox*. London, England: J&A Churchill Ltd, 1962
24. Poland GA, Neff JM: Smallpox vaccine: Problems and prospects. *Immunol Allergy Clin North Am* **23**(4):731-743, 2003
25. Centers for Disease Control and Prevention: Laboratory-acquired vaccinia virus infection—Virginia, 2008. *MMWR* **58**(29):797-800, 2009
26. Belongia EA, Naleway AL: Smallpox vaccine: The good, the bad, and the ugly. *Clin Med Res* **1**(2):87-92, 2003
27. Center for Disease Control and Prevention: Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine. *MMWR* **57**(8):207-208, 2008
28. Greenberg RN, Kennedy JS: ACAM2000: A newly licensed cell culture-based live vaccinia smallpox vaccine. *Expert Opin Investig Drugs* **17**(4):555-564, 2008
29. Handley L et al: The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. *Expert Rev Vaccines* **8**(7):841-850, 2009

30. <http://www.smallpox.army.mil/education/acam2000.asp>
31. Frey SE et al: Clinical responses to undiluted and diluted smallpox vaccine. *N Engl J Med* **346**(17):1265-1274, 2002
32. Cono J, Casey CG, Bell DM: Smallpox vaccination and adverse reactions. Guidance for clinicians. *MMWR Recomm Rep* **52**:1-28, 2003
33. Centers for Disease Control and Prevention: Vaccinia (smallpox) vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* **50**:1-25, 2001
34. Fulginiti VA et al: Smallpox vaccination: A review, part II. Adverse events. *Clin Infect Dis* **37**(2):251-271, 2003
35. Neff JM et al: Contact vaccinia—transmission of vaccinia from smallpox vaccination. *JAMA* **288**:1901-1905, 2002
36. Cleri DJ, Villota FJ, Porwancher RB: Smallpox, bioterrorism, and the neurologist. *Arch Neurol* **60**:489-494, 2003
37. Bartlett J et al: Smallpox vaccination in 2003: Key information for clinicians. *Clin Infect Dis* **36**:883-902, 2003
38. Halsell JS et al: Myopericarditis following smallpox vaccination among vaccinia-naïve US military personnel. *JAMA* **289**:3283-3289, 2003
39. Moyron-Quiroz JE et al: The smallpox vaccine induces an early neutralizing IgM response. *Vaccine* **10**(28):140-147, 2009
40. Tom WL, Kenner JR, Friedlander SF: Smallpox: Vaccine reactions and contraindications. *Dermatol Clin* **22**(3):275-289, 2004
41. Centers for Disease Control and Prevention: Update. Cardiac-related events during the civilian smallpox vaccination program—United States, 2003. *MMWR* **52**:492-496, 2003
42. Centers for Disease Control and Prevention: Progressive vaccinia in a military smallpox vaccinee—United States, 2009. *MMWR* **58**(19):532-536, 2009
43. Maurer DM, Harrington B, Lane JM: Smallpox vaccine: Contraindications, administration, and adverse reactions. *Am Fam Physician* **68**(5):889-896, 2003
44. Schwartz B, Lebwohl M: Complications of the smallpox vaccine. *Int J Dermatol* **44**(4):289-292, 2005
45. von Krempelhuber A et al: A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. *Vaccine* **28**(5):1209-1216, 2010
46. Bonilla-Guerrero B, Poland GA: Smallpox vaccines: Current and future. *J Lab Clin Med* **142**:252-257, 2003
47. Nalca A et al: Reemergence of monkeypox: Prevalence, diagnostics, and countermeasures. *Clin Infect Dis* **41**(12):1765-1771, 2005
48. Ligon BL: Monkeypox: A review of the history and emergence in the Western hemisphere. *Semin Pediatr Infect Dis* **15**(4):280-287, 2004
49. Reed KD et al: The detection of monkeypox in humans in the Western Hemisphere. *N Engl J Med* **350**(4):342-350, 2004
50. Di Giulio DB, Eckburg PB: Human monkeypox: An emerging zoonosis. *Lancet Infect Dis* **4**(1):15-25, 2004
51. Cho CT, Wenner HA: Monkeypox virus. *Bacteriol Rev* **37**(1):1-18, 1973
52. Weaver JR, Isaacs SN: Monkeypox virus and insights into its immunomodulatory proteins. *Immunol Rev* **225**:96-113, 2008
53. Pattyn SR: Monkeypoxvirus infections. *Rev Sci Tech* **19**(1):92-97, 2000
54. Breman JG: Monkeypox: An emerging infection for humans? In: *Emerging Infections*, 4th edition, edited by WM Scheld, WA Craig, JM Hughes. Washington DC, ASM Press, 2000
55. Huhn GD et al: Clinical characteristics of human monkeypox, and risk factors for severe disease. *Clin Infect Dis* **41**(12):1742-1751, 2005
56. Centers for Disease Control and Prevention: Update: Multistate outbreak of monkeypox—Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. *MMWR* **52**(27):642-646, 2003
57. Marriott KA, Parkinson CV, Morefield SI: Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. *Vaccine* **24**(26):581-588, 2008
58. Barraviera SR: Diseases caused by poxvirus—orf and milker's nodules: A review. *J Venom Anim Toxins incl Trop Dis* **11**(2):102-108, 2005
59. Werchniak AE et al: Milker's nodule in a healthy young woman. *J Am Acad Dermatol* **49**(5):910-911, 2003
60. Schuler G, Honigsmann H, Wolff K: The syndrome of milker's nodules in burn injury: Evidence for indirect viral transmission. *J Am Acad Dermatol* **6**(3):334-339, 1982
61. Lewis-Jones S: The zoonotic poxviruses. *Dermatol Nurs* **14**(2):79-82, 85-86, 2002

62. Groves RW, Wilson-Jones E, MacDonald DM: Human orf and milker's nodule: A clinicopathologic study. *J Am Acad Dermatol* **25**:2813-2818, 1961
63. Lewis-Jones S: Zoonotic poxvirus infections in humans. *Curr Opin Infect Dis* **17**(2):81-89, 2004
64. Shelley WB, Shelley ED: Farmyard pox: Parapox virus infection in man. *Br J Dermatol* **108**(6):725-727, 1983
65. Shelley WD, Shelley ED: Surgical treatment of farmyard pox: Orf, milker's nodule, bovine pustular stomatitis pox. *Cutis* **31**:256-257, 1983
66. Shelukhina EM et al: Clustered cases of paravaccinia in milkers. *J Hyg Epidemiol Microbiol Immunol* **30**(4):411-417, 1986
67. Mercer A et al: Molecular genetic analyses of parapoxviruses pathogenic for humans. *Arch Virol Suppl* **13**:25-34, 1997
68. Centers for Disease Control and Prevention: Orf virus infection in humans—New York, Illinois, California and Tennessee, 2004–2005. *MMWR* **55**(03):65-68, 2006
69. Cottone R et al: Analysis of genomic rearrangement and subsequent gene deletion of the attenuated orf virus strain D1707. *Virus Res* **56**(1):53-67, 1998
70. Gurel MS et al: Giant orf on the nose. *Eur J Dermatol* **12**(2):183-185, 2002
71. Mourtada I et al: Human orf and erythema multiforme. *Ann Dermatol Venereol* **127**(4):397-339, 2000
72. Dupre A et al: Orf and atopic dermatitis. *Br J Dermatol* **105**(1):103-104, 1981
73. Macfarlane AW: Human orf complicated by bullous pemphigoid. *Br J Dermatol* **137**(4):656-657, 1997
74. Geernick K et al: A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. *J Med Virol* **64**:54-59, 2001
75. Becker TM et al: Trends in molluscum contagiosum in the US, 1966–1983. *Sex Transm Dis* **13**(2):88-92, 1986
76. Dohil MA et al: The epidemiology of molluscum contagiosum in children. *J Am Acad Dermatol* **54**:47-54, 2006
77. Nizeki K, Kano O, Yoshiro K: An epidemic study of molluscum contagiosum: Relationship to swimming. *Dermatologica* **169**:197-198, 1984
78. Choong KY, Roberts LJ: Molluscum contagiosum, swimming and bathing: A clinical analysis. *Australas J Dermatol* **40**:89-92, 1999
79. Luke JD, Silverberg NB: Vertically transmitted molluscum contagiosum infection. *Pediatrics* **125**(2):e423-e425, 2010
80. Senkevich TG et al: The genome of molluscum contagiosum virus: Analysis and comparison with other poxviruses. *Virology* **233**(1):19-42, 1997
81. Smith K, Yeager J, Skelton H: Molluscum contagiosum: Its clinical, histopathologic, and immunohistochemical spectrum. *Int J Dermatol* **38**:664-672, 1999
82. Buggert JJ, Darai G: Recent advances in molluscum contagiosum virus research. *Arch Virol Suppl* **13**:35-47, 1997
83. Moss B et al: Immune-defense molecules of molluscum contagiosum virus, a human poxvirus. *Trends Microbiol* **8**(10):473-477, 2000
84. Gur I: The epidemiology of molluscum contagiosum in HIV-seropositive patients: A unique entity or insignificant finding? *Int J STD AIDS* **19**(8):503-506, 2008
85. Dohil MA, Prendiville JS: Treatment of molluscum contagiosum with oral cimetidine: Clinical experience in 13 patients. *Pediatr Dermatol* **13**(4):310-312, 1996
86. van der Wouden JC et al: Interventions for cutaneous molluscum contagiosum. *Cochrane Database Syst Rev* **4**:CD004767, 2009

